<?xml version='1.0' encoding='utf-8'?>
<document id="30350297"><sentence text="Characterizing the Pharmacokinetic Interaction Between Simeprevir and Odalasvir in Healthy Volunteers Using a Population Modeling Approach."><entity charOffset="55-65" id="DDI-PubMed.30350297.s1.e0" text="Simeprevir" /><entity charOffset="70-79" id="DDI-PubMed.30350297.s1.e1" text="Odalasvir" /><pair ddi="false" e1="DDI-PubMed.30350297.s1.e0" e2="DDI-PubMed.30350297.s1.e0" /><pair ddi="false" e1="DDI-PubMed.30350297.s1.e0" e2="DDI-PubMed.30350297.s1.e1" /></sentence><sentence text="The aim of this study was to characterize the pharmacokinetic drug-drug interaction (DDI) between simeprevir (NS3/4A protease inhibitor) and odalasvir (NS5A inhibitor) after oral administration to support the design and dose selection of clinical studies with this combination for the treatment of chronic hepatitis C infection (HCV)" /><sentence text=" Simeprevir and odalasvir plasma concentrations from 30 healthy subjects receiving these drugs in monotherapy as well as in combination were pooled and analyzed using a population pharmacokinetic modeling approach"><entity charOffset="1-11" id="DDI-PubMed.30350297.s3.e0" text="Simeprevir" /><entity charOffset="16-25" id="DDI-PubMed.30350297.s3.e1" text="odalasvir" /><pair ddi="false" e1="DDI-PubMed.30350297.s3.e0" e2="DDI-PubMed.30350297.s3.e0" /><pair ddi="false" e1="DDI-PubMed.30350297.s3.e0" e2="DDI-PubMed.30350297.s3.e1" /></sentence><sentence text=" Previous pharmacokinetic models developed to characterize the pharmacokinetics for each drug were used as starting point" /><sentence text=" The dual effect of simeprevir and odalasvir on their pharmacokinetic parameters was explored"><entity charOffset="20-30" id="DDI-PubMed.30350297.s5.e0" text="simeprevir" /><entity charOffset="35-44" id="DDI-PubMed.30350297.s5.e1" text="odalasvir" /><pair ddi="false" e1="DDI-PubMed.30350297.s5.e0" e2="DDI-PubMed.30350297.s5.e0" /><pair ddi="false" e1="DDI-PubMed.30350297.s5.e0" e2="DDI-PubMed.30350297.s5.e1" /></sentence><sentence text=" Simulations were performed to assess the impact of the DDI on exposure parameters" /><sentence text=" In presence of odalasvir, the relative bioavailability of simeprevir increased by 26% and the apparent clearance was reduced following competitive inhibition depending on odalasvir plasma concentrations, with an inhibitory constant (Ki) estimated to be 1610 ng/mL"><entity charOffset="16-25" id="DDI-PubMed.30350297.s7.e0" text="odalasvir" /></sentence><sentence text=" The apparent odalasvir clearance was reduced by simeprevir plasma concentrations following an Imax model, characterized by a maximum inhibitory effect of 46"><entity charOffset="49-59" id="DDI-PubMed.30350297.s8.e0" text="simeprevir" /></sentence><sentence text="7% and an IC50 of 257 ng/mL" /><sentence text=" Model-based simulations indicated that both Cmax and AUC24h increased for both drugs, when co-administered" /><sentence text=" The pharmacokinetic model adequately describes the time course of plasma concentrations and their variability when simeprevir and/or odalasvir were orally administered"><entity charOffset="116-126" id="DDI-PubMed.30350297.s11.e0" text="simeprevir" /><entity charOffset="134-143" id="DDI-PubMed.30350297.s11.e1" text="odalasvir" /><pair ddi="false" e1="DDI-PubMed.30350297.s11.e0" e2="DDI-PubMed.30350297.s11.e0" /><pair ddi="false" e1="DDI-PubMed.30350297.s11.e0" e2="DDI-PubMed.30350297.s11.e1" /></sentence><sentence text=" This model can be used as a first step to predict the exposures of concomitant administration of simeprevir and odalasvir in HCV-infected subjects"><entity charOffset="98-108" id="DDI-PubMed.30350297.s12.e0" text="simeprevir" /><entity charOffset="113-122" id="DDI-PubMed.30350297.s12.e1" text="odalasvir" /><pair ddi="false" e1="DDI-PubMed.30350297.s12.e0" e2="DDI-PubMed.30350297.s12.e0" /><pair ddi="false" e1="DDI-PubMed.30350297.s12.e0" e2="DDI-PubMed.30350297.s12.e1" /></sentence><sentence text=" Data from study AL355-602 (NCT02512562) were used for this analysis" /><sentence text="" /></document>